Reuters (8 July 2025) reported that Swiss authorities have approved Coartem Baby, pharmaceutical company Novartis’ first-ever medicine specifically designed to treat malaria in infants weighing less than five kilograms.
“Previously, no approved malaria treatment existed for newborns and small infants, forcing healthcare providers to adapt formulations intended for older children, which carried a significant risk of inaccurate dosing.
“This approval is expected to be swiftly followed by authorisations in eight African countries that were integral to the assessment process: Burkina Faso, Ivory Coast, Kenya, Malawi, Mozambique, Nigeria, Tanzania, and Uganda.”